Adebrelimab in combination with dalpiciclib and endocrine therapy as neoadjuvant treatment for HR+/HER2- early breast cancer: an exploratory study - PubMed
5 hours ago
- #breast cancer
- #neoadjuvant therapy
- #CDK4/6 inhibitor
- Adebrelimab combined with dalpiciclib and endocrine therapy was studied as neoadjuvant treatment for HR+/HER2- early breast cancer.
- The study involved postmenopausal women with stage II-III HR+/HER2- breast cancer, treated over five 28-day cycles before surgery.
- Primary endpoint was total pathologic complete response (tpCR), with one patient achieving tpCR (5%).
- 65% of patients showed radiological partial response, with an overall objective response rate (ORR) of 65%.
- Common grade ≥3 adverse events included neutropenia (50%), leukopenia (25%), and elevated liver enzymes.
- Three patients discontinued treatment due to adverse events, including one death.
- The regimen showed modest clinical activity but raised safety concerns requiring attention in clinical practice.